| 查看: 3929 | 回复: 17 | |||||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||||
[交流]
达比加群酯的SWOT分析项
|
|||||
|
老大让我做一个SWOT分析，这对一个没有THOMSON、没有Pharmaproject的立项工作者来说，只能空手套白狼了，暂时只想出以下几个分析项，请各位虫友补充啦。 S分析 用药方法的便利性 出血安全性得到FDA、EMA等机构的屡次肯定 曾经获得FDA下属委员会全票支持 其对卒中的预防效果明显优于华法林 有间接比较研究显示，达比加群酯的成本-效益特征与有效性特征优于利伐沙班 先后在德国和加拿大被授予Prix Galien最佳药物奖 曾经获得NICE的有条件推荐 上市后市场表现强劲，已经实现了重磅炸弹级别的销售额 W分析 出血事件—达比加群酯挥之不去的阴影 肾功能损伤与P-gp是达比加群酯在其用药过程中需要调整剂量的主要因素 RE-ALLGN失败，使得人工心脏瓣膜成为达比加群酯的禁忌症之一 价格昂贵 O分析 适应证发病率高，用药市场规模庞大 需要开发新的药物，以弥补华法林的不足 利伐沙班于ROCKET-AF试验中仅证实与华法林相比的非劣性 T分析 将面临来自阿哌沙班、利伐沙班、依度沙班的激烈竞争 [ Last edited by williamxiang on 2013-4-3 at 16:31 ] |
回复此楼» 收录本帖的淘帖专辑推荐
 研发工艺 | 泮托拉唑 |
» 猜你喜欢
药学专硕调剂
已经有0人回复
-
publcif的使用
已经有0人回复
-
药理学论文润色/翻译怎么收费?
已经有63人回复
-
求调剂
已经有2人回复
-
会计专硕求调剂
已经有0人回复
-
新加坡国立大学药学系化学生物学课题组招PhD
已经有14人回复
-
请教酰胺缩合反应
已经有4人回复
-
一志愿大连理工制药工程专硕086002，本科211，总分342
已经有0人回复
-
制药工程专业招收调剂，要求过国家线
已经有0人回复
-
五邑大学药物化学生物学团队-李兰清课题组招收调剂学生
已经有0人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 达比加群酯在中国获批
已经有17人回复
- 达比加群酯经过碱降解后产物会是什么结构？
已经有10人回复
- 达比加群酯甲磺酸盐 颜色
已经有10人回复
» 抢金币啦！回帖就可以得到:
-
中国农业科学院农业环境与可持续发展研究所博士后招聘
+1/281
-
【招聘】温州医科大学/附属医院/瓯江实验室李校堃院士团队诚聘博士后和科研人员
+1/191
-
西南交通大学医学院招收生物医学工程和材料与化工专业硕士研究生
+1/182
-
马尔文激光粒度+纳米粒径Zeta电位测试原始数据与Origin绘图V131/2039/8821
+1/91
-
删帖
+2/52
-
招收材料相关硕士研究生
+2/40
-
澳大利亚昆士兰大学化工学院招收全奖博士生2名
+1/26
-
汕头大学海洋与生命学科李升康教授团队招收生物类调剂生
+1/21
-
南京林业大学-国家级青年人才团队 招2026级博士、硕士（合成化学、植物化学方向）
+1/20
-
北京石油化工学院智能防腐涂层课题组招收2026级调剂研究生
+1/16
-
双一流大学湘潭大学“化工过程模拟与强化”国家地方联合工程研究中心招收各类博士生
+1/16
-
哈尔滨工业大学-大湾区大学2026年联合培养博士研究生春季招生-报名3月31号截至
+1/14
-
南京医科大学-谭磊课题组-诚招博士后
+1/10
-
西安工程大学环境与化学工程学院能源环境催化与先进材料课题组招生
+1/9
-
北京航空航天大学磁粒子成像课题组钟景教授招收2026年秋季“申请考核”博士
+1/8
-
欢迎来英国拉夫堡大学交流-结晶，蛋白质，AI，水处理等
+1/7
-
大连理工大学气体监测与环境催化团队诚聘副教授、助理教授及博士后3-4名
+1/6
-
欢迎调剂报考
+1/6
-
中国科学院大学纳米科学与技术学院-罗聃课题组诚招硕士研究生
+1/5
-
苏州高校招收08方向调剂
+1/3
18楼2013-09-10 18:04:01
★ ★ ★
小木虫: 金币+0.5, 给个红包，谢谢回帖
痴夷子皮: 金币+2, 谢谢交流，欢迎常来哦。 2013-04-07 08:32:18
小木虫: 金币+0.5, 给个红包，谢谢回帖
痴夷子皮: 金币+2, 谢谢交流，欢迎常来哦。 2013-04-07 08:32:18
|
Strengths The first novel anticoagulant to secure approval for stroke prevention in atrial fibrillation (AF), entering the US market in November 2010 No requirement for anticoagulation monitoring and dose adjustment, and no food effect In the RE-LY trial in AF, Pradaxa showed comparable to superior efficacy in stroke prevention, compared with warfarin, with equal to lower bleeding risk A subgroup analysis from RE-LY showed that Pradaxa 150 mg bid reduced the rate of stroke by 35% compared with well-controlled warfarin, irrespective of a patient's stroke risk Comparable to Lovenox in the prevention of major venous thromboembolism (VTE) and VTE-related mortality after both knee and hip replacement, according to RE-NOVATE data Equal efficacy to well-controlled warfarin in the treatment of acute VTE, but with a 37% reduction in major or clinically relevant bleeding risk over 6 months, according to RECOVER data |
2楼2013-04-03 10:38:46
★ ★ ★ ★ ★ ★
小木虫: 金币+0.5, 给个红包，谢谢回帖
williamxiang: 金币+5 2013-04-03 10:47:53
小木虫: 金币+0.5, 给个红包，谢谢回帖
williamxiang: 金币+5 2013-04-03 10:47:53
|
Weaknesses A superiority claim over warfarin in stroke prevention was rejected for inclusion in the label by the FDA A 110 mg doseage was not approved for use in patients at higher bleeding risk A higher risk of myocardial infarction was seen in RE-LY Twice daily dosing, compared with once daily for Xarelto Not approved in the US for VTE prevention post-surgery, unlike Xarelto which was approved in July 2011 Has faced some safety concerns, and the label was updated to mandate renal testing in high-risk patients Associated with a 6% rate of major gastrointestinal hemorrhage during each patient year on treatment Other gastrointestinal side effects, including dyspepsia, nausea and gastritis, are increased compared with warfarin (35% vs 24%) Current lack of antidote Very short half-life once removed from specially designed desiccant-containing packaging |
3楼2013-04-03 10:41:12
★
小木虫: 金币+0.5, 给个红包，谢谢回帖
小木虫: 金币+0.5, 给个红包，谢谢回帖
|
Opportunities Approval in AF opens up a blockbuster market, and Pradaxa could garner a greater share of the market in the near term due to its first mover advantage Pradaxa could be viewed as superior to Xarelto given Xarelto's lack of superiority to warfarin on an intent-to-treat basis seen in the ROCKET AF trial Despite the proven efficacy of warfarin in stroke prevention, it has a number of limitations, such as an increased risk of bleeding and the need for patient monitoring and dose adjustment, which has created an unmet need for safe and effective alternatives Approval in acute coronary syndrome (ACS); phase III trials in this setting began in December 2007 Development of competitor Eliquis in ACS was discontinued following high rates of bleeding in trials High cost and considerable copay required for Pradaxa may fade as insurers realize potential savings from increased avoidance of ischemic events and hospitalization AF is the most common sustained cardiac rhythm disturbance, and prevalence increases with age Up to 60% of cases of AF are caused by hypertension or coronary artery disease, which are increasing in prevalence in most Western societies ACS is the leading cause of death in the US and one of the most prevalent non-communicable diseases in the world |
4楼2013-04-03 10:53:35
